Chi‐square analysis demonstrated that elevated RASD2 expression independently predicted poor prognosis and significantly associated with aggressive clinicopathological features, including lymph node metastasis, extrathyroidal extension, and advanced TNM stage, but not with age, gender, or tumor size (Table 1). Here, RASD2 is linked to metastatic malignant neoplasm in the lymph nodes.